5115 ULMERTON ROAD, CLEARWATER, FL
Announces New Clinical Study Demonstrating Renuvion®’s Impact on Skin Quality
Apyx Medical Corporation Approves 2026 Share Incentive Plan
Reports Second Quarter 2026 Financial Results
Apyx Medical Corporation Reconstitutes Board Committees
Apyx Medical Corporation Appoints Stavros Vizirgianakis as Executive Chairman
New Study Shows Significant Improvement in Cellulite and Skin Laxity with Advanced Minimally Invasive Treatment Utilizing Avéli® and Renuvion®
Announces Retrospective Clinical Publication Evaluating Clinical Benefit of Renuvion® Used In Combination With Liposuction
Receives Expanded FDA 510(k) Clearance Adding Power Liposuction Capability to AYON Body Contouring System™
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Amended Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Specialized Disclosure Report
Correspondence
Submission Upload